加强美国食品药品监督管理局的药品安全监管权。 - Suppr

Bolstering the FDA's drug-safety authority.

作者信息

Schultz William B

机构信息

Zuckerman Spaeder LLP, Washington, DC, USA.

出版信息

N Engl J Med. 2007 Nov 29;357(22):2217-9. doi: 10.1056/NEJMp078212.

DOI:10.1056/NEJMp078212

PMID:18046024

Abstract

摘要

相似文献

Bolstering the FDA's drug-safety authority.

N Engl J Med. 2007 Nov 29;357(22):2217-9. doi: 10.1056/NEJMp078212.

Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.

Am Univ Law Rev. 2000;49:739-72.

Regulatory experts debate FDA's authority.

Am J Health Syst Pharm. 2007 May 1;64(9):910, 912. doi: 10.2146/news070040.

Marketing off-label uses to physicians: FDA's draft (mis)guidance.

Am J Bioeth. 2008 Mar;8(3):1-3. doi: 10.1080/15265160802116624.

Assessing supplement safety--the FDA's controversial proposal.

N Engl J Med. 2012 Feb 2;366(5):389-91. doi: 10.1056/NEJMp1113325. Epub 2012 Jan 25.

PLIVA v. Mensing: generic consumers' unfortunate hand.

Yale J Health Policy Law Ethics. 2012 Summer;12(2):209-63.

Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.

Seton Hall Law Rev. 2011;41(2):559-92.

Food and Drug Administration regulation and evaluation of vaccines.

Pediatrics. 2011 May;127 Suppl 1:S23-30. doi: 10.1542/peds.2010-1722E. Epub 2011 Apr 18.

Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.

Food Drug Law J. 2007;62(3):559-72.

Shifting terrain in the regulation of off-label promotion of pharmaceuticals.

N Engl J Med. 2009 Apr 9;360(15):1557-66. doi: 10.1056/NEJMhle0807695.

引用本文的文献

Analysis of Safety-Related Regulatory Actions for New Drugs in Japan by Nature of Identified Risks.

Pharmaceut Med. 2017;31(5):317-327. doi: 10.1007/s40290-017-0198-2. Epub 2017 Jul 13.

The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.

Drug Saf. 2014 Apr;37(4):283-94. doi: 10.1007/s40264-014-0150-2.

Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

CMAJ. 2014 May 13;186(8):E287-92. doi: 10.1503/cmaj.131850. Epub 2014 Mar 10.

Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2213-20. doi: 10.2215/CJN.05130513. Epub 2013 Aug 22.

Off-label use of rituximab in a multipayer insurance system.

J Oncol Pract. 2011 Mar;7(2):76-9. doi: 10.1200/JOP.2010.000042.

Assessing long-term drug safety: lessons (re) learned from raptiva.

Semin Cutan Med Surg. 2010 Mar;29(1):16-9. doi: 10.1016/j.sder.2010.01.001.

Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.

Drug Saf. 2009;32(11):1057-66. doi: 10.2165/11316670-000000000-00000.

Off-label prescribing: a call for heightened professional and government oversight.

J Law Med Ethics. 2009 Fall;37(3):476-86, 396. doi: 10.1111/j.1748-720X.2009.00408.x.

Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007.

Public Health Rep. 2008 Jul-Aug;123(4):527-30. doi: 10.1177/003335490812300415.

Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Br J Clin Pharmacol. 2008 Nov;66(5):689-94. doi: 10.1111/j.1365-2125.2008.03273.x. Epub 2008 Jul 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Bolstering the FDA's drug-safety authority.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献